Renal Cancer Treatment Decision-Making Tool - Primary cell culture for personalized therapy

SATT SUD EST



18 Novembre 2015

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

BACKGROUND

Renal cell carcinomas (RCC) showed poor prognosis in the metastatic phase, with a life expectancy of 3 months, prior to the development of anti-angiogenesis treatments.

3 main anti-angiogenesis treatments are available: sunitinib (Pfizer) as first-line treatment, everolimus (Novartis) as second line treatment and sorafenib (Bayer) as a second/third line treatment. Few (5-10%) RCC patients are resistant to sunitinib and treating them with the drug decreases their life expectancy.

The medical need is to predict patients response to reference therapies.

 

HOW IT WORKS

IRCAN Institute developed a method to isolate and cultivate kidney cancer cells from post surgery patient biopsies. (Pages G, PLoS One, March 2014)

This method can be used to predict patient response to the 3 reference therapies by in vitro assays (using the cell impedance technology developed by OdesiaNeoSciences™). Researchers showed significant correlation between sensitivity to targeted therapies on living patients and on cells derived from the initial tumor.

 

KEY BENEFITS vs. STATE OF THE ART

No predictive markers of anti-angiogenesis drugs efficacy are currently available

Our in vitro method:

  • Allows evaluating the best treatments for personalized management of RCC during the period following surgery: make the best choice for a second and even a third line treatment.
  • Avoids a 6-12 months period with inefficient and toxic treatments for the patient

 

RESULTS

IC50 of drugs was determined using the MTT assay on:

  • 786-O: reference sensitive RCC cell line
  • CC & M: 2 sunitinib-sensitive metastatic RCC patients cell lines
  • TF: sunitinib-resistant metastatic RCC patient cell line

Cells were sensitive when the IC50 was lower or equal to that in 786-O cells, and insensitive if the IC50 was higher to that in 786-O cells

*p<0.05, **p<0.01, ***p<0.0001, NS: non significant

 

APPLICATIONS

Cell culture for personalized medicine in oncology

Download the offer Download the offer

Newsletter